Combining TNF-α Inhibitors With IL-4,IL-17,IL-23,or JAK Inhibitors in Patients with Multiple,Severe Dermatologic Conditions and/or Gastrointestinal or Rheumatologic Disease
Restricted accessLetterFirst published online July, 2025
Combining TNF-α Inhibitors With IL-4,IL-17,IL-23,or JAK Inhibitors in Patients with Multiple,Severe Dermatologic Conditions and/or Gastrointestinal or Rheumatologic Disease
GoldSLSteinlaufAF.Efficacy and safety of dual biologic therapy in patients with inflammatory bowel disease: a review of the literature. Gastroenterol Hepatol (N Y). 2021;17(9):406-414.
4.
HrenMGGueninSKhattriS.Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease. J Am Acad Dermatol. 2024;91(1):138-140. doi:10.1016/j.jaad.2024.03.007
5.
HrenMGKhattriS.Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series. Ann Rheum Dis. 2024;83(10):1392-1393. doi:10.1136/ard-2024-225800
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
